MA54953A - Composés, compositions et procédés - Google Patents
Composés, compositions et procédésInfo
- Publication number
- MA54953A MA54953A MA054953A MA54953A MA54953A MA 54953 A MA54953 A MA 54953A MA 054953 A MA054953 A MA 054953A MA 54953 A MA54953 A MA 54953A MA 54953 A MA54953 A MA 54953A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805263P | 2019-02-13 | 2019-02-13 | |
| US201962877232P | 2019-07-22 | 2019-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54953A true MA54953A (fr) | 2021-12-22 |
Family
ID=72043948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054953A MA54953A (fr) | 2019-02-13 | 2020-02-12 | Composés, compositions et procédés |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11306077B2 (fr) |
| EP (1) | EP3923935A4 (fr) |
| JP (2) | JP2022520236A (fr) |
| KR (1) | KR20210126036A (fr) |
| CN (1) | CN113518618A (fr) |
| AU (1) | AU2020223228A1 (fr) |
| BR (1) | BR112021015639A2 (fr) |
| CA (1) | CA3129609A1 (fr) |
| CL (1) | CL2021002104A1 (fr) |
| CO (1) | CO2021010490A2 (fr) |
| CR (1) | CR20210426A (fr) |
| IL (1) | IL285302A (fr) |
| MA (1) | MA54953A (fr) |
| MX (1) | MX2021009669A (fr) |
| PE (1) | PE20212023A1 (fr) |
| PH (1) | PH12021551923A1 (fr) |
| SA (1) | SA521430021B1 (fr) |
| SG (1) | SG11202108552QA (fr) |
| TW (1) | TWI877136B (fr) |
| WO (1) | WO2020168011A1 (fr) |
| ZA (1) | ZA202105930B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49858A (fr) | 2017-08-09 | 2021-04-28 | Denali Therapeutics Inc | Composés, compositions et procédés |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| EP3723762A4 (fr) | 2017-12-13 | 2021-12-08 | Praxis Biotech LLC | Inhibiteurs de la voie de réponse intégrée au stress |
| BR112020023115A2 (pt) | 2018-06-05 | 2021-02-02 | Praxis Biotech LLC | inibidores da via integrada de resposta a tensão |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| CA3129067A1 (fr) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Composes de thioeno[3,2-b]pyridin-7-amine pour le traitement de la dysautonomie familiale |
| WO2020167624A1 (fr) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale |
| CA3142748A1 (fr) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulateurs de la voie de reponse integree au stress |
| EP4117780A1 (fr) | 2020-03-11 | 2023-01-18 | Evotec International GmbH | Modulateurs de la voie de réponse au stress intégrée |
| CA3195290A1 (fr) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulateurs de la voie de reponse integree au stress |
| MX2023004677A (es) * | 2020-10-22 | 2023-05-24 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| CN116761803A (zh) * | 2020-10-22 | 2023-09-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| PL4232154T3 (pl) | 2020-10-22 | 2025-02-24 | Evotec International Gmbh | Modulatory zintegrowanego szlaku odpowiedzi na stres |
| CR20230254A (es) * | 2020-12-18 | 2023-07-26 | Denali Therapeutics Inc | Formas sólidas de un compuesto |
| LU102921B1 (en) | 2022-03-25 | 2023-09-26 | Stratec Se | Consumable for sample processing in automated analyser |
| JP2025526814A (ja) * | 2022-08-08 | 2025-08-15 | シェンチェン チョンゲ バイオロジカル テクノロジー カンパニー リミテッド | 化合物、それを含む医薬組成物及びその用途 |
| EP4516773A4 (fr) | 2023-03-03 | 2025-10-29 | Daikin Ind Ltd | Composé contenant du fluor |
| WO2024185688A1 (fr) | 2023-03-03 | 2024-09-12 | ダイキン工業株式会社 | Polymère fluoré |
| WO2024185707A1 (fr) | 2023-03-03 | 2024-09-12 | ダイキン工業株式会社 | Composé contenant du fluor |
| WO2025019827A1 (fr) * | 2023-07-20 | 2025-01-23 | Denali Therapeutics Inc. | Formulation, forme posologique solide et méthodes |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| ES2221440T3 (es) | 1998-10-16 | 2004-12-16 | Daiichi Suntory Pharma Co Ltd | Derivados de acido aminofenoxiacetico como neuroprotectores. |
| AR024077A1 (es) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| AU2001249417A1 (en) * | 2000-04-26 | 2001-11-07 | Gliatech, Inc. | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| CA2443108A1 (fr) * | 2001-04-03 | 2002-10-17 | Merck & Co. Inc. | Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| CN101068794B (zh) | 2004-09-02 | 2012-12-19 | 沃泰克斯药物股份有限公司 | 可用作离子通道调控剂的喹唑啉 |
| WO2006125974A1 (fr) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | Quinoleines d’aminopiperidine et leurs analogues azaisosteriques presentant une activite antibacterienne |
| SG170767A1 (en) * | 2005-12-23 | 2011-05-30 | Zealand Pharma As | Modified lysine-mimetic compounds |
| US20080221100A1 (en) | 2006-10-20 | 2008-09-11 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| JP5274553B2 (ja) | 2007-06-15 | 2013-08-28 | アクテリオン ファーマシューティカルズ リミテッド | ３−アミノ−６−（１−アミノ−エチル）−テトラヒドロピラン誘導体 |
| NZ593891A (en) | 2008-12-12 | 2013-05-31 | Actelion Pharmaceuticals Ltd | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives |
| AU2010253820A1 (en) | 2009-05-28 | 2011-12-22 | President And Fellows Of Harvard College | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation |
| GEAP202213376A (en) | 2009-06-17 | 2022-02-25 | Vertex Pharmaceuticals Incorporated Us | Inhibitors of influenza viruses replication |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| CN103403002B (zh) | 2011-02-24 | 2016-06-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物 |
| DK2684880T3 (en) | 2011-03-10 | 2018-05-22 | Daiichi Sankyo Co Ltd | DISPIROPYRROLIDINE DERIVATIVES |
| AU2012245387C1 (en) | 2011-04-22 | 2016-05-05 | Signal Pharmaceuticals, Llc | Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| EP2814321B1 (fr) * | 2012-02-14 | 2018-09-26 | Syngenta Participations AG | Dérivés de cis(hétéro)arylcyclopropylcarboxamide utiles en tant que nematicides |
| CN104837820A (zh) | 2012-10-02 | 2015-08-12 | 大日本住友制药株式会社 | 咪唑衍生物 |
| KR102243637B1 (ko) | 2013-03-14 | 2021-04-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | 바이사이클릭 진통 화합물 |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2904794C (fr) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulateurs de la voie eif2 alpha |
| WO2015038778A1 (fr) | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | Activateurs substitués de l'urée-kinase eif2α |
| LT3126352T (lt) | 2014-04-04 | 2019-01-10 | Syros Pharmaceuticals, Inc. | Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai |
| WO2016044331A1 (fr) | 2014-09-17 | 2016-03-24 | Kalyra Pharmaceuticals, Inc. | Composés bicycliques |
| NZ730728A (en) | 2014-11-20 | 2022-04-29 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| EP3233087B1 (fr) | 2014-12-16 | 2019-10-02 | Axovant Sciences GmbH | Composés amide de quinuclidine à substituants géminal, en tant qu'agonistes des récepteurs nicotiniques de l'acétylcholine 7 |
| KR20170137725A (ko) | 2015-02-25 | 2017-12-13 | 윌리엄 마쉬 라이스 유니버시티 | 데스아세톡시투불리신 h 및 이의 유사체 |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CA2984848A1 (fr) | 2015-05-05 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | Derives de cyclohexane a substitution amido |
| TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| TWI844006B (zh) * | 2016-05-05 | 2024-06-01 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| KR20190015748A (ko) | 2016-06-08 | 2019-02-14 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Atf4 경로 억제제로서의 화학적 화합물 |
| US10851053B2 (en) * | 2016-06-08 | 2020-12-01 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI749024B (zh) | 2016-07-06 | 2021-12-11 | 美商艾克奎斯特有限責任公司 | 化合物及其於降低尿酸位準之用途 |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| US10093664B2 (en) | 2016-12-08 | 2018-10-09 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
| WO2018225093A1 (fr) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques utilisés comme inhibiteurs de la voie atf4 |
| KR102615098B1 (ko) * | 2017-06-09 | 2023-12-18 | 브리스톨-마이어스 스큅 컴퍼니 | 시클로프로필 우레아 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| BR112020000122A2 (pt) * | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças |
| CA3068395A1 (fr) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | Derives de 2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidine-3-yl)methyl)acetamide et composes apparentes servant d'inhibiteurs d'atf4 pour le traitement du cancer et d'autres maladies |
| MA49858A (fr) | 2017-08-09 | 2021-04-28 | Denali Therapeutics Inc | Composés, compositions et procédés |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| WO2019054430A1 (fr) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | Composé amide ayant un hétérocycle aromatique |
| CA3080808A1 (fr) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulateurs de la voie de reponse integree au stress |
| CN112218869A (zh) | 2017-11-02 | 2021-01-12 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| KR20200092332A (ko) | 2017-11-02 | 2020-08-03 | 칼리코 라이프 사이언시스 엘엘씨 | 통합된 스트레스 경로의 조절제 |
| CA3080971A1 (fr) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulateurs de la voie de reponse integree au stress |
| SG11202004009TA (en) | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| CA3080964A1 (fr) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulateurs de la voie de reponse integree au stress |
| EP3723762A4 (fr) | 2017-12-13 | 2021-12-08 | Praxis Biotech LLC | Inhibiteurs de la voie de réponse intégrée au stress |
| WO2019183589A1 (fr) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulateurs du facteur 2 d'initiation eucaryote |
| WO2019193540A1 (fr) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Dérivés hétéroaryles de formule (i) utilisés en tant qu'inhibiteurs d'atf4 |
| WO2019193541A1 (fr) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de cycle aromatiques bicycliques de formule (i) utilisés en tant qu'inhibiteurs d'atf4 |
| EP3820843A1 (fr) | 2018-07-09 | 2021-05-19 | GlaxoSmithKline Intellectual Property Development Limited | Composés chimiques |
| WO2020031107A1 (fr) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| IL287379B2 (en) * | 2019-04-23 | 2025-11-01 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| KR20220016467A (ko) | 2019-04-30 | 2022-02-09 | 칼리코 라이프 사이언시스 엘엘씨 | 통합된 스트레스 경로의 조절인자로서 치환된 사이클로알킬 |
| US20200347043A1 (en) | 2019-04-30 | 2020-11-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| US20230125481A1 (en) * | 2020-01-28 | 2023-04-27 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| CR20230254A (es) | 2020-12-18 | 2023-07-26 | Denali Therapeutics Inc | Formas sólidas de un compuesto |
-
2020
- 2020-02-12 SG SG11202108552QA patent/SG11202108552QA/en unknown
- 2020-02-12 AU AU2020223228A patent/AU2020223228A1/en not_active Abandoned
- 2020-02-12 EP EP20755645.7A patent/EP3923935A4/fr active Pending
- 2020-02-12 MA MA054953A patent/MA54953A/fr unknown
- 2020-02-12 PH PH1/2021/551923A patent/PH12021551923A1/en unknown
- 2020-02-12 JP JP2021547076A patent/JP2022520236A/ja not_active Withdrawn
- 2020-02-12 CR CR20210426A patent/CR20210426A/es unknown
- 2020-02-12 BR BR112021015639-9A patent/BR112021015639A2/pt unknown
- 2020-02-12 CN CN202080017506.7A patent/CN113518618A/zh active Pending
- 2020-02-12 WO PCT/US2020/018007 patent/WO2020168011A1/fr not_active Ceased
- 2020-02-12 CA CA3129609A patent/CA3129609A1/fr active Pending
- 2020-02-12 TW TW109104414A patent/TWI877136B/zh active
- 2020-02-12 KR KR1020217027796A patent/KR20210126036A/ko active Pending
- 2020-02-12 PE PE2021001317A patent/PE20212023A1/es unknown
- 2020-02-12 MX MX2021009669A patent/MX2021009669A/es unknown
-
2021
- 2021-05-28 US US17/334,587 patent/US11306077B2/en active Active
- 2021-08-02 IL IL285302A patent/IL285302A/en unknown
- 2021-08-10 CO CONC2021/0010490A patent/CO2021010490A2/es unknown
- 2021-08-10 CL CL2021002104A patent/CL2021002104A1/es unknown
- 2021-08-10 SA SA521430021A patent/SA521430021B1/ar unknown
- 2021-08-18 ZA ZA2021/05930A patent/ZA202105930B/en unknown
-
2022
- 2022-03-23 US US17/702,718 patent/US11958840B2/en active Active
-
2024
- 2024-09-10 JP JP2024156648A patent/JP2024166311A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021002104A1 (es) | 2022-04-08 |
| ZA202105930B (en) | 2025-03-26 |
| CA3129609A1 (fr) | 2020-08-20 |
| PH12021551923A1 (en) | 2022-08-01 |
| US11958840B2 (en) | 2024-04-16 |
| US20230114472A1 (en) | 2023-04-13 |
| EP3923935A4 (fr) | 2022-10-26 |
| SG11202108552QA (en) | 2021-09-29 |
| EP3923935A1 (fr) | 2021-12-22 |
| MX2021009669A (es) | 2021-10-13 |
| CN113518618A (zh) | 2021-10-19 |
| AU2020223228A1 (en) | 2021-08-26 |
| CO2021010490A2 (es) | 2021-08-30 |
| KR20210126036A (ko) | 2021-10-19 |
| IL285302A (en) | 2021-09-30 |
| US11306077B2 (en) | 2022-04-19 |
| TW202045164A (zh) | 2020-12-16 |
| BR112021015639A2 (pt) | 2021-10-05 |
| TWI877136B (zh) | 2025-03-21 |
| JP2024166311A (ja) | 2024-11-28 |
| US20210292311A1 (en) | 2021-09-23 |
| PE20212023A1 (es) | 2021-10-18 |
| WO2020168011A1 (fr) | 2020-08-20 |
| JP2022520236A (ja) | 2022-03-29 |
| CR20210426A (es) | 2021-09-30 |
| SA521430021B1 (ar) | 2024-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54953A (fr) | Composés, compositions et procédés | |
| MA54959A (fr) | Composés, compositions et procédés | |
| MA49858A (fr) | Composés, compositions et procédés | |
| EP3917927A4 (fr) | Immunomodulateurs, compositions et procédés associés | |
| MA54946A (fr) | Procédés et composés | |
| MA50063A (fr) | Composés, compositions et procédés | |
| MA54875A (fr) | Compositions oligonucléotidiques et procédés associés | |
| EP3823673A4 (fr) | Compositions anti-cd112r et procédés | |
| EP3806906A4 (fr) | Nouveaux composés cétogènes, compositions, procédés et utilisation de ceux-ci | |
| EP3380101A4 (fr) | Composés inhibiteurs d'eif4-a et procédés associés | |
| MA56032A (fr) | Composés, compositions et procédés d'utilisation | |
| EP3880194A4 (fr) | Composés deutérés, compositions et utilisations | |
| LT4084779T (lt) | 1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos | |
| DK3924443T3 (da) | Compositions | |
| EP3494119A4 (fr) | Composés et compositions, et utilisations associées | |
| MA52896A (fr) | Composés inhibiteurs de vmat2, compositions et méthodes associées | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| EP3871694A4 (fr) | Composition | |
| PL3967726T3 (pl) | Kompozycja utwardzalna | |
| EP4077318A4 (fr) | Composés | |
| EP4079787A4 (fr) | Composition durcissable | |
| EP3552017A4 (fr) | Composés, compositions et méthodes | |
| EP3981256A4 (fr) | Composition | |
| EP3941942A4 (fr) | Composition | |
| EP4079785A4 (fr) | Composition durcissable |